pharma · Duchenne muscular dystrophy (DMD) · JAK2V617F-positive high-risk Polycythemia Vera
ITALFARMACO S.P.A
Italfarmaco S.p.A.
Italfarmaco S.p.A is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Duchenne muscular dystrophy (DMD), JAK2V617F-positive high-risk Polycythemia Vera, Chronic myeloproliferativ
Cinisello Balsamo, IT HQ
1938 Founded
629 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Cinisello Balsamo, IT
- Founded
- 1938
- Employees
- 629
- Programs
- 7
- Drugs
- 17
- Patents
- 0
DSC/11/2357/44
Phase 2 · small molecule · Chronic myeloproliferative neoplasm
DSC/11/2357/44 for Chronic myeloproliferative neoplasm is a Phase 2 program (small_molecule) at Italfarmaco S.p.A. with 1 ClinicalTrials.gov record(s).
Internal code DSC/11/2357/44
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Italfarmaco S.p.A.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Chronic myeloproliferative neoplasm
- Status
- active
- Trials
- 1